BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 36125434)

  • 21. TMPRSS2:ERG fusion identifies a subgroup of prostate cancers with a favorable prognosis.
    Saramäki OR; Harjula AE; Martikainen PM; Vessella RL; Tammela TL; Visakorpi T
    Clin Cancer Res; 2008 Jun; 14(11):3395-400. PubMed ID: 18519769
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Advancing age within established Gleason score categories and the risk of prostate cancer-specific mortality (PCSM).
    Russo AL; Chen MH; Aizer AA; Hattangadi JA; D'Amico AV
    BJU Int; 2012 Oct; 110(7):973-9. PubMed ID: 22954029
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Absence of TMPRSS2:ERG fusions and PTEN losses in prostate cancer is associated with a favorable outcome.
    Yoshimoto M; Joshua AM; Cunha IW; Coudry RA; Fonseca FP; Ludkovski O; Zielenska M; Soares FA; Squire JA
    Mod Pathol; 2008 Dec; 21(12):1451-60. PubMed ID: 18500259
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical implications of TMPRSS2-ERG gene fusion expression in patients with prostate cancer treated with radical prostatectomy.
    Rubio-Briones J; Fernández-Serra A; Calatrava A; García-Casado Z; Rubio L; Bonillo MA; Iborra I; Solsona E; López-Guerrero JA
    J Urol; 2010 May; 183(5):2054-61. PubMed ID: 20303538
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The TMPRSS2:ERG rearrangement, ERG expression, and prostate cancer outcomes: a cohort study and meta-analysis.
    Pettersson A; Graff RE; Bauer SR; Pitt MJ; Lis RT; Stack EC; Martin NE; Kunz L; Penney KL; Ligon AH; Suppan C; Flavin R; Sesso HD; Rider JR; Sweeney C; Stampfer MJ; Fiorentino M; Kantoff PW; Sanda MG; Giovannucci EL; Ding EL; Loda M; Mucci LA
    Cancer Epidemiol Biomarkers Prev; 2012 Sep; 21(9):1497-509. PubMed ID: 22736790
    [TBL] [Abstract][Full Text] [Related]  

  • 26. TMPRSS2:ERG gene fusion predicts subsequent detection of prostate cancer in patients with high-grade prostatic intraepithelial neoplasia.
    Park K; Dalton JT; Narayanan R; Barbieri CE; Hancock ML; Bostwick DG; Steiner MS; Rubin MA
    J Clin Oncol; 2014 Jan; 32(3):206-11. PubMed ID: 24297949
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Distinct transcriptional repertoire of the androgen receptor in ETS fusion-negative prostate cancer.
    Berglund AE; Rounbehler RJ; Gerke T; Awasthi S; Cheng CH; Takhar M; Davicioni E; Alshalalfa M; Erho N; Klein EA; Freedland SJ; Ross AE; Schaeffer EM; Trock BJ; Den RB; Cleveland JL; Park JY; Dhillon J; Yamoah K
    Prostate Cancer Prostatic Dis; 2019 May; 22(2):292-302. PubMed ID: 30367117
    [TBL] [Abstract][Full Text] [Related]  

  • 28. ETS family-associated gene fusions in Japanese prostate cancer: analysis of 194 radical prostatectomy samples.
    Miyagi Y; Sasaki T; Fujinami K; Sano J; Senga Y; Miura T; Kameda Y; Sakuma Y; Nakamura Y; Harada M; Tsuchiya E
    Mod Pathol; 2010 Nov; 23(11):1492-8. PubMed ID: 20693979
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Significance of the TMPRSS2:ERG gene fusion in prostate cancer.
    Wang Z; Wang Y; Zhang J; Hu Q; Zhi F; Zhang S; Mao D; Zhang Y; Liang H
    Mol Med Rep; 2017 Oct; 16(4):5450-5458. PubMed ID: 28849022
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Analysis of fusion gene expression in prostate tumors by using single-end reads.
    Xie DD; Li JY; Wang Y; Chen L; Yu DX
    Genet Mol Res; 2013 Aug; 12(3):2886-94. PubMed ID: 24065644
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prognostic Utility of a New mRNA Expression Signature of Gleason Score.
    Sinnott JA; Peisch SF; Tyekucheva S; Gerke T; Lis R; Rider JR; Fiorentino M; Stampfer MJ; Mucci LA; Loda M; Penney KL
    Clin Cancer Res; 2017 Jan; 23(1):81-87. PubMed ID: 27663590
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tumor protein expression of the DNA repair gene BRCA1 and lethal prostate cancer.
    Stopsack KH; Gerke T; Zareba P; Pettersson A; Chowdhury D; Ebot EM; Flavin R; Finn S; Kantoff PW; Stampfer MJ; Loda M; Fiorentino M; Mucci LA
    Carcinogenesis; 2020 Jul; 41(7):904-908. PubMed ID: 32556091
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comprehensive metabolomics analysis of prostate cancer tissue in relation to tumor aggressiveness and TMPRSS2-ERG fusion status.
    Dudka I; Thysell E; Lundquist K; Antti H; Iglesias-Gato D; Flores-Morales A; Bergh A; Wikström P; Gröbner G
    BMC Cancer; 2020 May; 20(1):437. PubMed ID: 32423389
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Molecular genetic analyses of the TMPRSS2-ERG and TMPRSS2-ETV1 gene fusions in 50 cases of prostate cancer.
    Winnes M; Lissbrant E; Damber JE; Stenman G
    Oncol Rep; 2007 May; 17(5):1033-6. PubMed ID: 17390040
    [TBL] [Abstract][Full Text] [Related]  

  • 35. βIII-tubulin overexpression is an independent predictor of prostate cancer progression tightly linked to ERG fusion status and PTEN deletion.
    Tsourlakis MC; Weigand P; Grupp K; Kluth M; Steurer S; Schlomm T; Graefen M; Huland H; Salomon G; Steuber T; Wilczak W; Sirma H; Simon R; Sauter G; Minner S; Quaas A
    Am J Pathol; 2014 Mar; 184(3):609-17. PubMed ID: 24378408
    [TBL] [Abstract][Full Text] [Related]  

  • 36. TMPRSS2-ERG status is not prognostic following prostate cancer radiotherapy: implications for fusion status and DSB repair.
    Dal Pra A; Lalonde E; Sykes J; Warde F; Ishkanian A; Meng A; Maloff C; Srigley J; Joshua AM; Petrovics G; van der Kwast T; Evans A; Milosevic M; Saad F; Collins C; Squire J; Lam W; Bismar TA; Boutros PC; Bristow RG
    Clin Cancer Res; 2013 Sep; 19(18):5202-9. PubMed ID: 23918607
    [TBL] [Abstract][Full Text] [Related]  

  • 37. TMPRSS2-ERG fusion is frequently observed in Gleason pattern 3 prostate cancer in a Canadian cohort.
    Darnel AD; Lafargue CJ; Vollmer RT; Corcos J; Bismar TA
    Cancer Biol Ther; 2009 Jan; 8(2):125-30. PubMed ID: 19029822
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Genome-wide linkage analysis of TMPRSS2-ERG fusion in familial prostate cancer.
    Hofer MD; Kuefer R; Maier C; Herkommer K; Perner S; Demichelis F; Paiss T; Vogel W; Rubin MA; Hoegel J
    Cancer Res; 2009 Jan; 69(2):640-6. PubMed ID: 19147579
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Early detection of clinically significant prostate cancer at diagnosis: a prospective study using a novel panel of TMPRSS2:ETS fusion gene markers.
    Chan SW; Nguyen PN; Violette P; Brimo F; Taguchi Y; Aprikian A; Chen JZ
    Cancer Med; 2013 Feb; 2(1):63-75. PubMed ID: 24133629
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Gene expression profiles in prostate cancer: identification of candidate non-invasive diagnostic markers.
    Mengual L; Ars E; Lozano JJ; Burset M; Izquierdo L; Ingelmo-Torres M; Gaya JM; Algaba F; Villavicencio H; Ribal MJ; Alcaraz A
    Actas Urol Esp; 2014 Apr; 38(3):143-9. PubMed ID: 24206626
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.